April 5, 2021 10:41 AM EDTUpdated April 6, 02:21 PM

Watch out, Bristol Myers — J&J is right behind you; Blake Byers leaps out from GV to do his own thing

John Carroll

Editor & Founder

We’ve learned that J&J has now finished its rolling application for the BCMA-targeted cilta-cel, which one analyst believes will put them about 8 or 9 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Watch out, Bristol Myers — J&J is right behind you; Blake Byers leaps out from GV to do his own thing

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

At least seven drugmakers say they will participate in round two of IRA negotiations

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

Where the money is: The top 100 venture investors in biotech

How AI can address ongoing challenges in the life sciences industry

Watch out, Bris­tol My­ers — J&J is right be­hind you; Blake By­ers leaps out from GV to do his own thing

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Watch out, Bristol Myers — J&J is right behind you; Blake Byers leaps out from GV to do his own thing